Association between glycemic control and patient-reported outcomes in adults with type 1 diabetes in Japan: the SAGE study subanalysis.

Aims/introduction: Psychosocial aspects and the quality of life (QOL) of individuals with diabetes are important for achieving glycemic control and treatment goals. Here, we describe patient-reported outcomes (PROs) of Japanese adults with type 1 diabetes (T1D) and evaluate the association thereof with glycemic control.
Materials and Methods: This subanalysis of a subgroup of 528 Japanese participants in the SAGE study of adults with T1D used data on glycosylated hemoglobin (HbA1c) and PRO scores [Hypoglycemia Fear Survey-II (HFS-II), Problem Areas In Diabetes (PAID), Insulin Treatment Satisfaction Questionnaire (ITSQ), and Audit of Diabetes-Dependent QOL (ADDQoL)] and summarized the score by the predefined age groups (26-44-years: n = 208, 45-64-years: n = 217, and ≥ 65-years: n = 103). The association between PROs, achieving HbA1c < 7.0%, and individualized targets was explored using multivariate logistic regression analysis.
Results: The HFS-II and PAID scores were lower, and the ITSQ score was higher in the ≥ 65-years group than in the younger groups with a linear trend of better scores with increasing age ( P for trend < 0.05). ADDQoL scores were similar across the age groups, and present QOL (ADDQoL subscale) tended to improve with age ( P for trend < 0.05). Achieving HbA1c < 7.0% and individualized targets were associated with satisfaction with insulin treatment regarding glycemic control.
Conclusion: In Japanese adults with T1D, the impact on psychosocial aspects and QOL varied across age groups, with a trend of improving scores with age, potentially in relation to the less stringent glycemic control targets adopted in older individuals. Glycemic control was significantly associated with treatment satisfaction.
Supplementary Information: The online version contains supplementary material available at 10.1007/s13340-023-00668-4.
Competing Interests: Conflict of interestRN received honoraria from Sanofi, Medtronic Japan, Nippon Boehringer Ingelheim, Takeda Pharmaceutical, KISSEI PHARMACEUTICAL, Novartis Pharma, Eli Lilly Japan, Novo Nordisk Pharma, MSD, Astellas Pharma, and Abbott; and subsidies or donations from Taisho Pharmaceutical, Ono Pharmaceutical, Takeda Pharmaceutical, Nippon Boehringer Ingelheim, and Abbott. AS declares that he has no conflict of interest. NA received honoraria from Novo Nordisk Pharma and Eli Lilly Japan. MM received honoraria from Sanofi, Eli Lilly Japan, Novo Nordisk Pharma, Abbott Japan, Sumitomo Pharma, Kyowa Kirin, Nippon Boehringer Ingelheim, and Orizuru Therapeutics; research funding from Novo Nordisk Pharma; and subsidies or donations from Sysmex and Nissui. YT is an employee of Sanofi. HI received honoraria from Novo Nordisk Pharma, Sanofi, Terumo, and Sumitomo Pharma; and subsidies or donations from LifeScan Japan, Novo Nordisk Pharma, Sumitomo Pharma, and Taisho Pharmaceutical.
(© The Japan Diabetes Society 2023, corrected publication 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.)